drugset
drugset / Trial / NCT06150664

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

NCT06150664 ↗

Phase 1 Recruiting 85 enrolled Compass Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

Timeline

Start
2024-03-19
Primary completion
2026-12
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CTX-8371 Unknown 3 mg/kg Intravenous
Subject CTX-8371 Unknown 10 mg/kg Intravenous

Indications

Hodgkins lymphoma head and neck squamous cell carcinoma melanoma non-small cell lung carcinoma triple-negative breast carcinoma